AGO is attracting attention from three directions at once. An analyst upgrade, a sharp drop in short positions, and record-low options bearishness landed on the same day — pointing in the same direction.
Roth Capital's Harry Fong upgraded AGO to Buy this morning. The price target moved to $85, up 6.25% from $80. The stock trades at $68.40. That implies roughly 24% upside to the new target alone.
Keefe, Bruyette & Woods maintains an Outperform with a $97 target. UBS holds a Buy at $94. The average analyst target across the coverage sits at $91.00. All three firms see significant room to run from current levels.
The upgrade arrives after a rough stretch. AGO has fallen 7.8% over the past month and 8.8% in the day following its August earnings release. Roth's move signals at least one firm thinks the sell-off has gone too far.
Short interest dropped 16.5% in a single week. Shares short fell to 2.08 million as of September 24. Short interest now stands at 4.5% of free float, down from a higher base earlier this month.
The lending market confirms there is no stress on the short side. Availability sits at 2,179% — roughly 29 million shares available to borrow against the 2 million currently on loan. Cost to borrow is just 0.50%. Bears face no friction unwinding, and none is being added.
The ORTEX short score has declined from 47.9 on September 16 to 43.0 on September 24. That trend aligns with the falling short interest.
The put-call ratio hit 0.466 on September 24. That is the lowest reading in 52 weeks. It sits 2.15 standard deviations below the 20-day mean of 0.64.
The PCR has been falling consistently since late August, when it sat above 0.80. The shift from defensive to aggressive call positioning over four weeks is notable. Options traders appear to be positioning for a move higher well before today's analyst upgrade.
See the live data behind this article on ORTEX.
Open AGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
